Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vitae Pharmaceuticals, a developer of small molecule medicines, has reacquired full rights to its renin inhibitor program and is advancing the program towards the clinic.
Subscribe to our email newsletter
The program was previously the subject of a partnership with GlaxoSmithKline’s cardiovascular centre of excellence for drug discovery unit.
Vitae’s other research programs include a substantial collaboration with Boehringer-Ingelheim on a diabetes program targeting 11 beta hydroxysteroid dehydrogenase, a Bace program for Alzheimer’s disease and a multi-kinase cancer program.
Richard Gregg, chief scientific officer of Vitae, said: “We believe our renin program has the strong potential to deliver a best-in-class drug, and we plan to aggressively advance our lead towards the clinic in 2009. We expect to target hypertension, diabetic nephropathy, congestive heart failure and related cardiovascular indications after completing investigational new drug-enabling toxicity studies.”